- Home
- MAGH vs SLS Comparison
MAGH vs SLS Comparison
Compare MAGH & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAGH | SLS |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.4M | 208.0M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | MAGH | SLS |
|---|---|---|
| Price | $6.85 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 1.2M | ★ 4.4M |
| Earning Date | 12-23-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $11,752,129.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7,194.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $0.77 |
| 52 Week High | $6.94 | $2.48 |
Technical Indicators
Market Signals| Indicator | MAGH | SLS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 66.47 |
| Support Level | N/A | $1.39 |
| Resistance Level | N/A | $2.00 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 0.00 | 89.73 |
Price Performance
Historical ComparisonAbout MAGH Magnitude International Ltd Ordinary Shares
Magnitude International Ltd is providing electrical installation services to customers in both the private and public sectors in Singapore. It includes the planning, design, material selection, installation, testing, commissioning and certification of the electrical equipment/systems to be installed. The Group's revenue is derived from Singapore.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.